Deals
Deal activity by volume related to cybersecurity decreased by 29% year-on-year in 2023 in the pharma industry
Credit: Bert van Dijk/Getty images.
Powered by
Analysis of the key themes driving deal activity reveals that cybersecurity accounted for 30 pharma deals between 2019 and 2023, worth a total value of $675m, according to GlobalData’s Deals database covering mergers and acquisitions, private equity, venture financing, equity offerings and partnerships.
The $4m equity offering by Aclid was the largest disclosed deal in 2023, while the $2m equity offering by PainChek was the largest disclosed deal in 2022.
In volume terms, cybersecurity related deal activity decreased by 29% year-on-year in 2023 and increased by 40% year-on-year in 2022.
Deal activity related to cybersecurity in the global pharma industry in the last five years
Top deals related to cybersecurity in the pharma industry in the last five years
Deal volume by deal type for cybersecurity related deals in the pharma industry in the last five years
Partnership accounted for the highest number of deals in the last five years, with 7 deals, followed by Licensing agreements (6 deals) and Acquisition (5 deals).
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Deals database provides comprehensive coverage across industries tracking market activity of global mergers & acquisitions, including asset acquisitions/divestments; private equity deals (PE); venture finance deals (VC); equity offerings, including IPOs, follow-on offerings, and private placements; debt offerings, including private placements, ESG bonds and loans; partnerships; and licensing agreements.
This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumored deals.
